Novel Lys63-linked ubiquitination of IKKβ induces STAT3 signaling

Cell Cycle

Volumn 13, Issue 24, 2014, Pages 3964-3976

  Gallo, Leandro H ^a   Meyer, April N ^a   Motamedchaboki, Khatereh ^b   Nelson, Katelyn N ^a   Haas, Martin ^c   Donoghue, Daniel J ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BURNHAM INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cell proliferation; IKK ; Inflammatory signaling; K 63 ubiquitination; Mass spectrometry; Multiple myeloma; NF B; Oncogenesis; Polyubiquitination; STAT3

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; I KAPPA B KINASE BETA; INTERLEUKIN 6; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE; PEPTIDE; PROTEIN BINDING; TRANSCRIPTION FACTOR; UBE2N PROTEIN, HUMAN; UBE2V1 PROTEIN, HUMAN; UBIQUITIN CONJUGATING ENZYME;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONJUGATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE MUTATION; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LIQUID CHROMATOGRAPHY; LYS63 LINKED UBIQUITINATION; MULTIPLE MYELOMA; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; TANDEM MASS SPECTROMETRY; UBIQUITINATION; AMINO ACID SEQUENCE; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; MOLECULAR GENETICS; MUTATION; PATHOLOGY; PHOSPHORYLATION;

AMINO ACID SEQUENCE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HEK293 CELLS; HUMANS; I-KAPPA B KINASE; LYSINE; MOLECULAR SEQUENCE DATA; MULTIPLE MYELOMA; MUTATION; NF-KAPPA B; PEPTIDES; PHOSPHORYLATION; PROTEIN BINDING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TANDEM MASS SPECTROMETRY; TRANSCRIPTION FACTORS; UBIQUITIN-CONJUGATING ENZYMES; UBIQUITINATION;

EID: 84920612688     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2014.988026     Document Type: Article

References (75)

1. Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM. Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res 2010; 70:4005-14; PMID:20424119; http://dx.doi.org/ 10.1158/0008-5472.CAN-09-3912
2. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004; 117:225-37; PMID:15084260; http://dx.doi.org/10.1016/S0092-8674(04)00302-2
3. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11:191-8; PMID:15685170; http://dx.doi.org/10.1038/nm1185
4. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11:183-90; PMID:15685173; http://dx.doi.org/10.1038/nm1166
5. Tanaka M, Fuentes ME, Yamaguchi K, Durnin MH, Dalrymple SA, Hardy KL, Goeddel DV. Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice. Immunity 1999; 10:421-9; PMID:10229185; http://dx.doi.org/ 10.1016/S1074-7613(00)80042-4
6. Andreakos E, Smith C, Kiriakidis S, Monaco C, de Martin R, Brennan FM, Paleolog E, Feldmann M, Foxwell BM. Heterogeneous requirement of IkappaB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy. Arthritis Rheum 2003; 48:1901-12; PMID:12847684; http://dx.doi.org/10.1002/art. 11044
7. Aupperle K, Bennett B, Han Z, Boyle D, Manning A, Firestein G. NF-kappa B regulation by I kappa B kinase-2 in rheumatoid arthritis synoviocytes. J Immunol 2001; 166:2705-11; PMID:11160335; http://dx. doi.org/10.4049/jimmunol.166.4.2705
8. Zhang G, Li J, Purkayastha S, Tang Y, Zhang H, Yin Y, Li B, Liu G, Cai D. Hypothalamic programming of systemic ageing involving IKK-beta, NF-kappaB and GnRH. Nature 2013; 497:211-6; PMID:23636330; http://dx.doi.org/10.1038/nature12143
9. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12:115-30; PMID:17692804; http://dx.doi.org/ 10.1016/j.ccr.2007.07.004
10. Gilmore TD. Multiple myeloma: lusting for NF-kappaB. Cancer Cell 2007; 12:95-7; PMID:17692798; http://dx.doi.org/10.1016/j.ccr.2007.07.010
11. Wertz IE, Dixit VM. Signaling to NF-kappaB: regulation by ubiquitination. Cold Spring Harbor Perspect Biol 2010; 2:a003350; PMID:20300215; http://dx. doi.org/10.1101/cshperspect.a003350
12. Chen ZJ. Ubiquitination in signaling to and activation of IKK. Immunol Rev 2012; 246:95-106; PMID:22435549; http://dx.doi.org/10.1111/j.1600-065X.2012.01108.x
13. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell 2006; 22:245-57; PMID:16603398; http://dx.doi.org/10.1016/j.molcel.2006.03.026
14. Yamazaki K, Gohda J, Kanayama A, Miyamoto Y, Sakurai H, Yamamoto M, Akira S, Hayashi H, Su B, Inoue J. Two mechanistically and temporally distinct NF-kappaB activation pathways in IL-1 signaling. Sci Signal 2009; 2:ra66; PMID:19843958; http://dx.doi. org/10.1126/scisignal.2000387
15. Rahighi S, Ikeda F, Kawasaki M, Akutsu M, Suzuki N, Kato R, Kensche T, Uejima T, Bloor S, Komander D, et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF-kappaB activation. Cell 2009; 136:1098-109; PMID:19303852; http://dx.doi. org/10.1016/j.cell.2009.03.007
16. Skaug B, Chen J, Du F, He J, Ma A, Chen ZJ. Direct, noncatalytic mechanism of IKK inhibition by A20. Mol Cell 2011; 44:559-71; PMID:22099304; http:// dx.doi.org/10.1016/j.molcel.2011.09.015
17. Bhoj VG, Chen ZJ.Ubiquitylation in innate and adaptive immunity. Nature 2009; 458:430-7; PMID:19325622; http://dx.doi.org/10.1038/nature07959
18. Chen ZJ, Sun LJ. Nonproteolytic functions of ubiquitin in cell signaling. Mol Cell 2009; 33:275-86; PMID:19217402; http://dx.doi.org/10.1016/j.molcel. 2009.01.014
19. Yang WL, Zhang X, Lin HK. Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development. Oncogene 2010; 29:4493-503; PMID:20531303; http://dx.doi.org/ 10.1038/onc.2010.190
20. Xia ZP, Sun L, Chen X, Pineda G, Jiang X, Adhikari A, Zeng W, Chen ZJ. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 2009; 461:114-9; PMID:19675569; http://dx.doi.org/10. 1038/nature08247
21. Lamothe B, Besse A, Campos AD, Webster WK, Wu H, Darnay BG. Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 autoubiquitination is a critical determinant of I kappa B kinase activation. J Biol Chem 2007; 282:4102-12; PMID:17135271; http://dx.doi.org/10.1074/jbc.M609 503200
22. Windheim M, Stafford M, Peggie M, Cohen P. Inter-leukin-1 (IL-1) induces the Lys63-linked polyubiquitination of IL-1 receptor-associated kinase 1 to facilitate NEMO binding and the activation of IkappaBalpha kinase. Mol Cell Biol 2008; 28:1783-91; PMID:18180283; http://dx.doi.org/10.1128/MCB. 02380-06
23. Conze DB, Wu CJ, Thomas JA, Landstrom A, Ashwell JD. Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor- and toll-like recep-tor-mediated NF-kappaB activation. Mol Cell Biol 2008; 28:3538-47; PMID:18347055; http://dx.doi. org/10.1128/MCB.02098-07
24. Wu CJ, Conze DB, Li T, Srinivasula SM, Ashwell JD. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation [corrected]. Nat Cell Biol 2006; 8:398-406; PMID:16547522; http://dx.doi.org/10.1038/ncb1384
25. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471:467-72; PMID:21430775; http://dx.doi.org/ 10.1038/nature09837
26. Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C, Spina V, Bruscaggin A, Monti S, Cerri M, e al. Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma. Blood 2011; 118:4930-4; PMID:21881048; http://dx.doi.org/10.1182/blood-2011-06-359166
27. Bea S, Valdes-Mas R, Navarro A, Salaverria I, Martin-Garcia D, Jares P, Gine E, Pinyol M, Royo C, Nadeu F, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A 2013; 110:18250-5; PMID:24145436; http:// dx.doi.org/10.1073/pnas.1314608110
28. Delhase M, Hayakawa M, Chen Y, Karin M. Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science 1999; 284:309-13; PMID:10195894; http://dx.doi. org/10.1126/science.284.5412.309
29. Meyer AN, Drafahl KA, McAndrew CW, Gilda JE, Gallo LH, Haas M, Brill LM, Donoghue DJ. Tyrosine phosphorylation allows integration of multiple signaling inputs by IKKbeta. PLoS One 2013; 8:e84497; PMID:24386391; http://dx.doi.org/10.1371/journal. pone.0084497
30. Liu S, Misquitta YR, Olland A, Johnson MA, Kelleher KS, Kriz R, Lin LL, Stahl M, Mosyak L. Crystal structure of a human IkappaB kinase beta asymmetric dimer. J Biol Chem 2013; 288:22758-67; PMID:23792959
31. Wada K, Niida M, Tanaka M, Kamitani T. Ro52-mediated monoubiquitination of IKK{beta} down-regulates NF-kappaB signalling. J Biochem 2009; 146:821-32; PMID:19675099; http://dx.doi.org/ 10.1093/jb/mvp127
32. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002; 2:927-37; PMID:12459731; http://dx.doi.org/10.1038/nrc952
33. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr. Stat3 as an oncogene. Cell 1999; 98:295-303; PMID:10458605; http:// dx.doi.org/10.1016/S0092-8674(00)81959-5
34. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005; 41:2502-12; PMID:16199153; http://dx.doi. org/10.1016/j.ejca.2005.08.016
35. Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang WC, Hait NC, Allegood JC, Price MM, Avni D, et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 2013; 23:107-20; PMID:23273921; http://dx.doi.org/10.1016/j.ccr.2012.11.013
36. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10:105-15; PMID:10023775; http://dx.doi.org/ 10.1016/S1074-7613(00)80011-4
37. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798-809; PMID:19851315; http://dx. doi.org/10.1038/nrc2734
38. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7:41-51; PMID:17186030; http://dx.doi.org/10.1038/nri1995
39. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, Anderson KC. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NFkappa B. Blood 1996; 87:1104-12; PMID:8562936
40. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB. Nuclear factor-kappaB and STAT3 are constitutively active in CD138 C cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004; 103:3175-84; PMID:15070700; http://dx.doi.org/ 10.1182/blood-2003-06-2151
41. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 2011; 12:715-23; PMID:21772280; http://dx.doi.org/ 10.1038/ni.2060
42. Liu H, Sadygov RG, Yates JR, 3rd. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004; 76:4193-201; PMID:15253663; http://dx.doi.org/ 10.1021/ac0498563
43. Huttlin EL, Jedrychowski MP, Elias JE, Goswami T, Rad R, Beausoleil SA, Villen J, Haas W, Sowa ME, Gygi SP. A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 2010; 143:1174-89; PMID:21183079; http://dx.doi.org/10.1016/j.cell. 2010.12.001
44. Pulvino M, Liang Y, Oleksyn D, DeRan M, Van Pelt E, Shapiro J, Sanz I, Chen L, Zhao J. Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitinconjugating enzyme Ubc13-Uev1A. Blood 2012; 120:1668-77; PMID:22791293; http://dx.doi.org/ 10.1182/blood-2012-02-406074
45. Zhou H, Wertz I, O'Rourke K, Ultsch M, Seshagiri S, Eby M, Xiao W, Dixit VM. Bcl10 activates the NFkappaB pathway through ubiquitination of NEMO. Nature 2004; 427:167-71; PMID:14695475; http:// dx.doi.org/10.1038/nature02273
46. Abbott DW, Wilkins A, Asara JM, Cantley LC. The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr Biol 2004; 14:2217-27; PMID:15620648; http:// dx.doi.org/10.1016/j.cub.2004.12.032
47. Zhou AY, Shen RR, Kim E, Lock YJ, Xu M, Chen ZJ, Hahn WC. IKKepsilon-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/ cIAP2/TRAF2 E3 ubiquitin ligase complex. Cell Rep 2013; 3:724-33; PMID:23453969; http://dx.doi.org/ 10.1016/j.celrep.2013.01.031
48. Carter RS, Pennington KN, Arrate P, Oltz EM, Ballard DW. Site-specific monoubiquitination of IkappaB kinase IKKbeta regulates its phosphorylation and persistent activation. J Biol Chem 2005; 280:43272-9; PMID:16267042; http://dx.doi.org/10.1074/jbc. M508656200
49. Niida M, Tanaka M, Kamitani T. Downregulation of active IKK beta by Ro52-mediated autophagy. Mol Immunol 2010; 47:2378-87; PMID:20627395; http:// dx.doi.org/10.1016/j.molimm.2010.05.004
50. Lee DF, Kuo HP, Liu M, Chou CK, Xia W, Du Y, Shen J, Chen CT, Huo L, Hsu MC, et al. KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol Cell 2009; 36:131-40; PMID:19818716; http://dx.doi.org/10.1016/j.molcel. 2009.07.025
51. Udeshi ND, Svinkina T, Mertins P, Kuhn E, Mani DR, Qiao JW, Carr SA. Refined preparation and use of anti-diglycine remnant (K-epsilon-GG) antibody enables routine quantification of 10000s of ubiquitination sites in single proteomics experiments. Mol Cell Proteomics 2013; 12:825-31; PMID:23266961; http://dx. doi.org/10.1074/mcp.O112.027094
52. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001; 412:346-51; PMID:11460167; http://dx.doi.org/10.1038/35085597
53. Lamb A, Chen J, Blanke SR, Chen LF. Helicobacter pylori activates NF-kappaB by inducing Ubc13-mediated ubiquitination of lysine 158 of TAK1. J Cell Biochem 2013; 114:2284-92; PMID:23606331; http://dx. doi.org/10.1002/jcb.24573
54. Liang L, Fan Y, Cheng J,Cheng D, Zhao Y, Cao B,Ma L, An L, Jia W, Su X, Yang J, Zhang H. TAK1 ubiquitination regulates doxorubicin-induced NF-kappaB activation. Cell Signal 2013; 25:247-54; PMID:22981905; http://dx.doi.org/10.1016/j. cellsig.2012.09.003
55. An L, Jia W, Yu Y, Zou N, Liang L, Zhao Y, Fan Y, Cheng J, Shi Z, Xu G, et al. Lys63-linked polyubiquitination of BRAF at lysine 578 is required for BRAFmediated signaling. Sci Rep 2013; 3:2344; PMID:23907581
56. Webster MK, D'Avis PY, Robertson SC, Donoghue DJ. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol Cell Biol 1996; 16:4081-7; PMID:8754806
57. Tavormina PL, Bellus GA, Webster MK, Bamshad MJ, Fraley AE, McIntosh I, Szabo J, Jiang W, Jabs EW, Wilcox WR, et al. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am J Hum Genet 1999; 64:722-31; PMID:10053006; http://dx.doi.org/10.1086/302275
58. Drafahl KA, McAndrew CW, Meyer AN, Haas M, Donoghue DJ. The receptor tyrosine kinase FGFR4 negatively regulates NFkappaB signaling. PLoS One 2010; 5:e14412; PMID:21203561; http://dx.doi.org/ 10.1371/journal.pone.0014412
59. Carrano AC, Dillin A, Hunter T. A Kruppel-like factor downstream of the E3 ligase WWP-1 mediates dietary-restriction-induced longevity in Caenorhabditis elegans. Nat Commun 2014; 5:3772; PMID:24805825; http://dx.doi.org/10.1038/ncomms4772
60. Meyer AN, McAndrew CW, Donoghue DJ. Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells. Cancer Res 2008; 68:7362-70; PMID:18794123; http://dx.doi. org/10.1158/0008-5472.CAN-08-0575
61. Jiao X, Wood LD, Lindman M, Jones S, Buckhaults P, Polyak K, Sukumar S, Carter H, Kim D, Karchin R, Sjoblom T. Somatic mutations in the Notch, NF-KB, PIK3CA, and Hedgehog pathways in human breast cancers. Genes Chromosomes Cancer 2012; 51:480-9; PMID:22302350; http://dx.doi.org/10.1002/gcc.21935
62. Stephens P, Edkins S, Davies H, Greenman C, Cox C, Hunter C, Bignell G, Teague J, Smith R, Stevens C, et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 2005; 37:590-2; PMID:15908952; http://dx.doi.org/10.1038/ng1571
63. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314:268-74; PMID:16959974; http://dx.doi.org/10.1126/ science.1133427
64. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318:1108-13; PMID:17932254; http://dx.doi.org/10.1126/science.1145720
65. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609-15; PMID:21720365; http://dx.doi.org/ 10.1038/nature10166
66. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, Guan Y, Janakiraman V, Jaiswal BS, et al. Recurrent R-spondin fusions in colon cancer. Nature 2012; 488:660-4; PMID:22895193; http://dx.doi.org/10.1038/nature 11282
67. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010; 466:869-73; PMID:20668451; http://dx.doi.org/10.1038/ nature09208
68. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, Bandla S, Imamura Y, Schumacher SE, Shefler E, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 2013; 45:478-86; PMID:23525077; http://dx.doi.org/ 10.1038/ng.2591
69. Bettegowda C, Agrawal N, Jiao Y, Wang Y, Wood LD, Rodriguez FJ, Hruban RH, Gallia GL, Binder ZA, Riggins CJ, et al. Exomic sequencing of four rare central nervous system tumor types. Oncotarget 2013; 4:572-83; PMID:23592488
70. Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, Dean M, Huang Y, Jia W, Zhou Q, Tang A, et al. Wholegenome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013; 45:1459-63; PMID:24121792; http://dx.doi.org/ 10.1038/ng.2798
71. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki H, et al. Integrated molecular analysis of clearcell renal cell carcinoma. Nat Genet 2013; 45:860-7; PMID:23797736; http://dx.doi.org/10.1038/ng.2699
72. Tarpey PS, Behjati S, Cooke SL, Van Loo P, Wedge DC, Pillay N, Marshall J, O'Meara S, Davies H, Nik-Zainal S, et al. Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nat Genet 2013; 45:923-6; PMID:23770606; http://dx. doi.org/10.1038/ng.2668
73. CancerGenome Atlas ResearchNetwork.Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487:330-7; PMID:22810696; http:// dx.doi.org/10.1038/nature11252
74. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory J, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in smallcell lung cancer. Nat Genet 2012; 44:1111-6; PMID:22941189; http://dx.doi.org/10.1038/ng.2405
75. Zang ZJ, Ong CK, Cutcutache I, Yu W, Zhang SL, Huang D, Ler LD, Dykema K, Gan A, Tao J, et al. Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. Cancer Res 2011; 71:29-39; PMID:21097718; http:// dx.doi.org/10.1158/0008-5472.CAN-10-1749